Palatin Technologies Shares Progress on Obesity Pipeline and Fiscal Performance for Q1 2026 #USA #Palatin_Technologies #Princeton #Obesity_Treatment #MC4R_Agonists
0
0
0
0
Hashtag
#Palatin_Technologies
Advertisement · 728 × 90
Palatin Technologies Finalizes $18.2 Million Public Offering to Boost Drug Development #USA #biopharmaceuticals #Palatin_Technologies #Princeton #PTN
0
0
0
0
Palatin Technologies Unveils Promising MC4R Agonist Data at ObesityWeek 2025 #USA #Atlanta #Palatin_Technologies #MC4R_agonist #PL7737
0
0
0
0
Palatin Technologies Expands Its Offerings with $15.8 Million Public Offering Announcement #USA #Palatin_Technologies #Biopharmaceutical #Princeton,_NJ #Public_Offering
0
0
0
0
Palatin Technologies Secures €5.5 Million Milestone for Retinal Disease Treatment with Boehringer Ingelheim #United_States #Boehringer_Ingelheim #Palatin_Technologies #Princeton #Retinal_Disease
0
0
0
0
Palatin Technologies Implements 1-for-50 Reverse Stock Split to Enhance Share Value #United_States #Palatin_Technologies #Princeton #OTCQB #Reverse_Stock_Split
0
0
0
0
Palatin Technologies Presents Strong Preclinical Results of PL7737 for Obesity Treatment #USA #Palatin_Technologies #Princeton #MC4R_agonist #PL7737
0
0
0
0
Palatin Technologies Unveils Innovative Findings on Melanocortin Agonists at ARVO 2025 #United_States #Palatin_Technologies #Diabetic_Retinopathy #Cranbury,_New_Jersey #melanocortin_agonists
0
0
0
0
Palatin Technologies Finalizes Reduced Public Offering: A Closer Look #USA #Palatin_Technologies #Cranbury #Biomedical_Research #OTC_Market
0
0
0
0
Palatin Technologies Unveils Significant Progress in Dry Eye Disease Treatment with PL9643 at ARVO 2025 #Palatin_Technologies #Dry_Eye_Disease #PL9643
0
0
0
0
Palatin Technologies Shifts to OTC Pink After NYSE American Delisting Notification #United_States #Palatin_Technologies #Cranbury #OTC_Pink #NYSE_American
0
0
0
0
Palatin Technologies Secures $11.5 Million in Financing to Avoid NYSE Delisting #United_States #Palatin_Technologies #Cranbury #NYSE_American #MC4R_peptides
0
0
0
0
Palatin Technologies Launches $23 Million Public Offering Targeting Healthcare Investments #United_States #healthcare #Palatin_Technologies #PTN #Cranbury,_New_Jersey
0
0
0
0
Palatin Unveils Dual-Action Glaucoma Therapy PL9588 with Promising Preclinical Outcomes #United_States #Palatin_Technologies #Cranbury #Glaucoma_Treatment #PL9588
0
0
0
0
Palatin Technologies Shows Promise in Obesity Treatment with New Findings from Phase 2 Study on MC4R Agonists #United_States #Palatin_Technologies #Cranbury #tirzepatide #Bremelanotide
0
0
0
0
Palatin Technologies Takes Firm Steps to Appeal NYSE Delisting Notice #USA #Palatin_Technologies #Cranbury #NYSE_Delisting #Stock_Compliance
0
0
0
0
Palatin Technologies Faces NYSE Delisting Amidst Appeal Plans for Compliance #United_States #Palatin_Technologies #Cranbury #NYSE_Compliance #Delisting_Appeal
0
0
0
0
Palatin Technologies Showcases Promising Phase 2b Results for Diabetic Kidney Disease Treatment #United_States #Boston #Palatin_Technologies #Diabetic_Nephropathy #Melanocortin_Agonist
0
0
0
0
Palatin Technologies Achieves Promising Results with New Obesity Treatment Combining MC4R Agonist and Tirzepatide #United_States #Palatin_Technologies #Cranbury #tirzepatide #Bremelanotide
0
0
0
0
Promising Phase 2 Results for PL8177 in Treating Ulcerative Colitis Show Clinical Remission in Patients #United_States #Ulcerative_Colitis #Palatin_Technologies #PL8177 #Cranbury
0
0
0
0
Palatin Technologies Achieves Milestone in Obesity Study and Financial Performance in Q2 FY2025 #USA #Palatin_Technologies #Cranbury #tirzepatide #MC4R_agonist
0
0
0
0
Palatin Technologies Unveils $4.7 Million Direct Offering and Private Placement for Future Innovations #United_States #Palatin_Technologies #Cranbury #Biopharmaceutical #stock_offering
0
0
0
0
Palatin Technologies Completes Phase 2 Study on Obesity Drug Combination's Effectiveness #USA #Palatin_Technologies #Cranbury #GLP-1_tirzepatide #MC4R_bremelanotide
0
0
0
0
Palatin Technologies Anticipates Major Corporate Milestones for 2025 in Obesity Treatment and Other Medications #United_States #Palatin_Technologies #Cranbury #tirzepatide #MC4R_agonist
0
0
0
0
Palatin Technologies Reports Successful Phase IIb BREAKOUT Study for Type 2 Diabetic Nephropathy Treatment #United_States #Palatin_Technologies #Cranbury #Bremelanotide #Diabetic_Nephropathy
0
0
0
0
Palatin Technologies Secures $3.4 Million from Warrant Exercise with New Investor Agreement #USA #Palatin_Technologies #Cranbury #NYSE_PTN #Melanocortin
0
0
0
0
Palatin Completes Enrollment for Phase 2 Trial of New Ulcerative Colitis Treatment, PL8177 #USA #Ulcerative_Colitis #Palatin_Technologies #PL8177 #Cranbury
0
0
0
0